Conditions: Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: 
Enrollment: 83
Healthy volunteers: no

Brief summary:
The main purpose of this study is to assess the optimum dose of the following medications when they are given together:

* BIBW 2992 and paclitaxel (Taxol)
* BIBW 2992 and paclitaxel and bevacizumab (Avastin)
* BIBW 2992 and carboplatin
* BIBW 2992 and paclitaxel and carboplatin The effect of the different drug combinations will also be assessed.

Detailed description:

Arms:
arm 1: BIBW2992 + Paclitaxel arm 2: BIBW2992 + Paclitaxel + Bevacizumab arm 3: BIBW2992 + Carboplatin arm 4: BIBW2992 +Paclitaxel + Carboplatin

Interventions: intervention 1: Paclitaxel intervention 2: Carboplatin intervention 3: BIBW 2992 intervention 4: Paclitaxel intervention 5: BIBW2992 intervention 6: Paclitaxel intervention 7: Carboplatin intervention 8: Bevacizumab intervention 9: BIBW 2992 intervention 10: BIBW 2992
Intervention descriptions: intervention 1: Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle. intervention 2: AUC6 given on day 1 of 21 day cycle intervention 3: Escalating dose cohorts intervention 4: Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle. intervention 5: MTD dose of part A intervention 6: 175mg/m2 given on Day 1 of 21 Day cycle intervention 7: AUC6 given on day 1 of 21 day cycle intervention 8: Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle intervention 9: Escalating dose cohorts intervention 10: Escalating dose cohorts

Protocol document: